No Photo Available

Last Update

2017-02-12T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Hjalmar Lagast?

Dr. Hjalmar Lagast

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Shire plc

Position, Clinical Trials

Solvay Pharmaceuticals , Inc.

Vice President Clinical Development

NPS Pharmaceuticals , Inc.

Manager, Government Affairs and Health Economics

Solvay S.A

Senior Vice President GLOBAL CLINICAL OPERATIONS

Abbott Laboratories company

Affiliations

Founder
OnPoint Clinical Consulting LLC

Deputy To Chief Medical Officer, Vice President of Clinical Operations and Medical Affairs and Member of Pharmaceutical Management
Abbott Products Inc

Education

Diploma of Doctor in Medicine

Université Libre de Bruxelles

M.D.

Web References (15 Total References)


Dr. Hjalmar Lagast - OnPoint Clinical Consulting, LLC

www.onpointclinicalconsulting.com [cached]

Dr. Hjalmar Lagast

...
Dr. Hjalmar Lagast
...
Dr. Hjalmar Lagast is a drug development consultant and founder of OnPoint Clinical Consulting, LLC, based in Bridgewater, NJ. He has decades of experience and has worked with and represented some of the most renowned names in health and medicine.
As VP Clinical Development at NPS Pharmaceuticals, now Shire Pharmaceuticals, Dr. Lagast completed and analyzed the results of the pivotal trial "REPLACE", which is the largest placebo-controlled study in the treatment of chronic hypoparathyroidism. He was also in charge of setting up and running the open label extension studies following REPLACE, which took place in the USA and in Hungary. In parallel to the clinical program, he worked collaboratively with the Market Access team on the epidemiology of the disease and on the patient perceptions of their disease through an innovative website questionnaire.
NPS Pharmaceuticals He led the team for the submission of the Biologics License Application to the FDA and the Marketing Authorization Application to the EMA and oversaw the multiple components of these applications. He took personal responsibility for the writing of the clinical overview section and clinical study reports. He drove the team for preparation to the Advisory Committee meeting, participated in the review of the briefing book, presented at the meeting and answered questions. Similarly, he prepared for the expert group meeting organized by the Committee for Human Medicinal Products (EMA), presented the results of new analyses and answered the questions raised by regulatory authorities during the review and at the meeting.
For both NPS products, Natpara and Gattex, he initiated the Medical Affairs activities. He led the setup, the organization, the training of the Medical Science Liaison group as well as the publication strategy for these compounds and the drafting of the abstracts, manuscripts, posters etc. He is an author of 5 manuscripts and 39 accepted abstracts on Natpara and hypoparathyroidism.
Solvay Pharma From 2007 to 2010, in his role of Sr. VP Global Clinical Operations he had responsibility for the organization and the execution of all clinical trials for Solvay Pharmaceuticals, now Abbott/Abbvie. He was instrumental in making the Quintiles-Solvay Alliance work and as a result, drove down by 50% the duration of clinical trials. Besides this operational role, he was also a member of the Strategic and Scientific Review Committee that approved the synopsis, the protocol, the study report for each study from Phase I to IV and the submission documents for every compound from 2005 to 2010.
In his prior role of VP US Clinical Development, he had responsibility for the development projects in the following therapeutic areas: gasteroenterology, central nervous system, women's health and men's health, cardiovascular and flu vaccines.
He led all the teams and facets of US Medical Affairs for a similar range of therapeutic areas, while launching/re-launching a number of compounds on the US market.
While working for Solvay Pharma Canada in Toronto, he held several positions in Scientific Affairs and Commercial Operations.
Institut Jules Bordet Prior to joining the industry, he had worked several years in hospitals in Belgium and in Switzerland (Hôpital Cantonal de Genève) while completing his specialization in Internal Medicine with a practice centered on Infectious Diseases and Oncology. He participated as a co-investigator in several trials of innovative antibiotics in patients with these severe infections.
He obtained his Diploma of Doctor in Medicine at the Université Libre de Bruxelles. HUG
He is comfortable interacting in multicultural teams and speaks several languages.
He volunteers at Camp Kudzu, in Georgia, that allows kids with diabetes to spend a few days having fun and learning about diabetes.
...
Dr. Lagast is a drug development consultant available to work with your team. Contact him today at (908) 432-9620.


Press Releases

www.solvaypharmaceuticals-us.com [cached]

Hjalmar Lagast, M.D., Named Vice President, Clinical Operations and Medical Affairs, and Deputy to the Chief Medical Officer for Solvay Pharmaceuticals, Inc. June 08, 2001 Solvay Pharmaceuticals, Inc. introduces Hjalmar Lagast, M.D., as its new vice president of clinical operations and medical affairs and deputy to the chief medical officer.


Marijuana Policy Project: United States

www.mpp.org [cached]

Such problems appeared in only "a small portion of the patients in our clinical trials," says Dr. Hjalmar Lagast, a vice president for Solvay Pharmaceuticals, which makes Marinol.He notes that the drug comes in three strengths, allowing doctors to pick the right dose.By the early '90s, at the height of the U.S. AIDS epidemic, many patients so preferred marijuana to Marinol that they would use the street drug regardless of legality or safety.Abrams and a few others began pushing the government to permit new studies of marijuana to find out what these patients were doing to themselves.

Officials again resisted, and some researchers became convinced the government would never allow evidence of pot's possible benefits to emerge.


Is Pot Good For You? :: St. Louis Raver :: Dedicated To The Positive Side Of The Rave Scene

www.stlouisraver.com [cached]

Such problems appeared in only "a small portion of the patients in our clinical trials," says Dr. Hjalmar Lagast, a vice president for Solvay Pharmaceuticals, which makes Marinol.He notes that the drug comes in three strengths, allowing doctors to pick the right dose.By the early '90s, at the height of the U.S. AIDS epidemic, many patients so preferred marijuana to Marinol that they would use the street drug regardless of legality or safety.


Showing selected news article

www.ukcia.org [cached]

Dr. Hjalmar Lagast, a vice president for Solvay Pharmaceuticals, which makes Marinol.He notes that the drug comes in three strengths, allowing doctors to pick the right dose.By the early '90s, at the height of the U.S. AIDS epidemic, many patients so preferred marijuana to Marinol that they would use the street drug regardless of legality or safety.

Similar Profiles

Other People with this Name

Other people with the name Lagast

Cedric Lagast

Lieven Lagast
Johnson Controls , Inc.

Ronny Lagast
Mountain Hyundai

Daniel Lagast
Mountain Hyundai

Heidi Lagast

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory